Woodline Partners’s Zevra Therapeutics ZVRA Stock Holding History

Woodline Partners’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$68.6M	Buy	4,785,771 +1,334,828	+39%	+$14.8M	0.21%	119
2026 Q1	$32.2M	Buy	3,450,943 +99	+0%	+$892	0.12%	226
2025 Q4	$30.9M	Sell	3,450,844 -25,299	-0.7%	-$239K	0.12%	224
2025 Q3	$33.1M	Sell	3,476,143 -1,139,533	-25%	-$11.4M	0.16%	184
2025 Q2	$40.7M	Buy	4,615,676 +51	+0%	+$414	0.21%	134
2025 Q1	$34.6M	Buy	4,615,625 +476,032	+11%	+$3.78M	0.22%	140
2024 Q4	$34.5M	Buy	4,139,593 +90,940	+2%	+$776K	0.23%	136
2024 Q3	$28.1M	Buy	4,048,653 +2,901,070	+253%	+$19.7M	0.24%	138
2024 Q2	$5.62M	Buy	1,147,583 +137,966	+14%	+$654K	0.05%	330
2024 Q1	$5.86M	Buy	+1,009,617	New	+$6.21M	0.05%	342

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Woodline Partners's ZVRA Position: Q2 2026 in Review

Woodline Partners increased its Zevra Therapeutics (ZVRA) stake by 39% in Q2 2026, buying an estimated $14.8M and bringing the position to 4,785,771 shares worth $68.6M. The position accounts for 0.21% of the portfolio, ranked #119.

Woodline Partners first reported a position in ZVRA in Q1 2024 and has held it in 10 quarters since. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

Woodline Partners held 4,785,771 shares of Zevra Therapeutics worth $68.6M as of Q2 2026.
Woodline Partners bought 1,334,828 Zevra Therapeutics shares in Q2 2026, an estimated $14.8M.
Zevra Therapeutics made up 0.21% of Woodline Partners's portfolio in Q2 2026, its #119 holding.
Woodline Partners first reported a position in Zevra Therapeutics in Q1 2024 and has held it in 10 quarters since.
157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.